1887

Abstract

The threat of highly pathogenic avian influenza (HPAI) H5N1 viruses to cause the next pandemic remains a major concern. Here, we evaluated the cross-protection induced by natural infection of human seasonal influenza strains or immunization with trivalent inactivated influenza vaccine (TIV) against HPAI H5N1 (A/Vietnam/1203/2004) virus in ferrets. Groups were treated with PBS (group A), infected with H1N1 (group B) or H3N2 (group C) virus, or immunized with TIV (group D). Twelve weeks after the last treatment, serological assays revealed that groups B and C, but not group D, sustained moderate immunogenicity against homologous viruses; cross-reactivity against the H5N1 virus was not detected in any group. Following challenge with A/Vietnam/1203/2004 (H5N1) virus, only groups B and C exhibited attenuated viral loads leading to 100 % survival. Our data suggest that natural infection with human seasonal strains could potentially provide better heterosubtypic protection against HPAI H5N1 virus infection compared to TIV immunization.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.058636-0
2014-04-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/4/793.html?itemId=/content/journal/jgv/10.1099/vir.0.058636-0&mimeType=html&fmt=ahah

References

  1. Air G. M.. ( 1981; ). Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. . Proc Natl Acad Sci U S A 78:, 7639–7643. [CrossRef] [PubMed]
    [Google Scholar]
  2. Beigel J. H., Farrar J., Han A. M., Hayden F. G., Hyer R., de Jong M. D., Lochindarat S., Nguyen T. K., Nguyen T. H.. & other authors ( 2005; ). Avian influenza A (H5N1) infection in humans. . N Engl J Med 353:, 1374–1385. [CrossRef] [PubMed]
    [Google Scholar]
  3. Bodewes R., Kreijtz J. H., Baas C., Geelhoed-Mieras M. M., de Mutsert G., van Amerongen G., van den Brand J. M., Fouchier R. A., Osterhaus A. D., Rimmelzwaan G. F.. ( 2009; ). Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. . PLoS ONE 4:, e5538. [CrossRef] [PubMed]
    [Google Scholar]
  4. Bodewes R., Kreijtz J. H., Geelhoed-Mieras M. M., van Amerongen G., Verburgh R. J., van Trierum S. E., Kuiken T., Fouchier R. A., Osterhaus A. D., Rimmelzwaan G. F.. ( 2011; ). Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. . J Virol 85:, 2695–2702. [CrossRef] [PubMed]
    [Google Scholar]
  5. Bragstad K., Jørgensen P. H., Handberg K., Hammer A. S., Kabell S., Fomsgaard A.. ( 2007; ). First introduction of highly pathogenic H5N1 avian influenza A viruses in wild and domestic birds in Denmark, Northern Europe. . Virol J 4:, 43. [CrossRef] [PubMed]
    [Google Scholar]
  6. Brewoo J. N., Powell T. D., Jones J. C., Gundlach N. A., Young G. R., Chu H., Das S. C., Partidos C. D., Stinchcomb D. T., Osorio J. E.. ( 2013; ). Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. . Vaccine 31:, 1848–1855. [CrossRef] [PubMed]
    [Google Scholar]
  7. Cattoli G., Monne I., Fusaro A., Joannis T. M., Lombin L. H., Aly M. M., Arafa A. S., Sturm-Ramirez K. M., Couacy-Hymann E.. & other authors ( 2009; ). Highly pathogenic avian influenza virus subtype H5N1 in Africa: a comprehensive phylogenetic analysis and molecular characterization of isolates. . PLoS ONE 4:, e4842. [CrossRef] [PubMed]
    [Google Scholar]
  8. Chen Z., Kim L., Subbarao K., Jin H.. ( 2012; ). The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. . Vaccine 30:, 2516–2522. [CrossRef] [PubMed]
    [Google Scholar]
  9. Claas E. C., Osterhaus A. D., van Beek R., De Jong J. C., Rimmelzwaan G. F., Senne D. A., Krauss S., Shortridge K. F., Webster R. G.. ( 1998; ). Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. . Lancet 351:, 472–477. [CrossRef] [PubMed]
    [Google Scholar]
  10. He X. S., Holmes T. H., Zhang C., Mahmood K., Kemble G. W., Lewis D. B., Dekker C. L., Greenberg H. B., Arvin A. M.. ( 2006; ). Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. . J Virol 80:, 11756–11766. [CrossRef] [PubMed]
    [Google Scholar]
  11. Heiny A. T., Miotto O., Srinivasan K. N., Khan A. M., Zhang G. L., Brusic V., Tan T. W., August J. T.. ( 2007; ). Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. . PLoS ONE 2:, e1190. [CrossRef] [PubMed]
    [Google Scholar]
  12. Hoft D. F., Babusis E., Worku S., Spencer C. T., Lottenbach K., Truscott S. M., Abate G., Sakala I. G., Edwards K. M.. & other authors ( 2011; ). Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. . J Infect Dis 204:, 845–853. [CrossRef] [PubMed]
    [Google Scholar]
  13. Kreijtz J. H., de Mutsert G., van Baalen C. A., Fouchier R. A., Osterhaus A. D., Rimmelzwaan G. F.. ( 2008; ). Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. . J Virol 82:, 5161–5166. [CrossRef] [PubMed]
    [Google Scholar]
  14. Kreijtz J. H., Suezer Y., de Mutsert G., van den Brand J. M., van Amerongen G., Schnierle B. S., Kuiken T., Fouchier R. A., Löwer J.. & other authors ( 2009; ). Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. . Vaccine 27:, 6296–6299. [CrossRef] [PubMed]
    [Google Scholar]
  15. Lamb R. A., Zebedee S. L., Richardson C. D.. ( 1985; ). Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. . Cell 40:, 627–633. [CrossRef] [PubMed]
    [Google Scholar]
  16. Lambert L. C., Fauci A. S.. ( 2010; ). Influenza vaccines for the future. . N Engl J Med 363:, 2036–2044. [CrossRef] [PubMed]
    [Google Scholar]
  17. Lee L. Y., Ha L. A., Simmons C., de Jong M. D., Chau N. V., Schumacher R., Peng Y. C., McMichael A. J., Farrar J. J.. & other authors ( 2008; ). Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. . J Clin Invest 118:, 3478–3490.[PubMed]
    [Google Scholar]
  18. Lee B. J., Lee S. H., Song M. S., Pascua P. N., Kwon H. I., Park S. J., Kim E. H., Decano A., Kim S. M.. & other authors ( 2013; ). Adjuvant efficacy of mOMV against avian influenza virus infection in mice. . J Microbiol 51:, 682–688. [CrossRef] [PubMed]
    [Google Scholar]
  19. Moskophidis D., Kioussis D.. ( 1998; ). Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. . J Exp Med 188:, 223–232. [CrossRef] [PubMed]
    [Google Scholar]
  20. Nabel G. J., Fauci A. S.. ( 2010; ). Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. . Nat Med 16:, 1389–1391. [CrossRef] [PubMed]
    [Google Scholar]
  21. Pappaioanou M.. ( 2009; ). Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic?. Comp Immunol Microbiol Infect Dis 32:, 287–300. [CrossRef] [PubMed]
    [Google Scholar]
  22. Sakabe S., Iwatsuki-Horimoto K., Horimoto T., Nidom C. A., Quynh Le M., Takano R., Kubota-Koketsu R., Okuno Y., Ozawa M., Kawaoka Y.. ( 2010; ). A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. . Antiviral Res 88:, 249–255. [CrossRef] [PubMed]
    [Google Scholar]
  23. Schulman J. L., Kilbourne E. D.. ( 1965; ). Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. . J Bacteriol 89:, 170–174.[PubMed]
    [Google Scholar]
  24. Tompkins S. M., Zhao Z. S., Lo C. Y., Misplon J. A., Liu T., Ye Z., Hogan R. J., Wu Z., Benton K. A.. & other authors ( 2007; ). Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. . Emerg Infect Dis 13:, 426–435. [CrossRef] [PubMed]
    [Google Scholar]
  25. Wang T. T., Tan G. S., Hai R., Pica N., Ngai L., Ekiert D. C., Wilson I. A., García-Sastre A., Moran T. M., Palese P.. ( 2010; ). Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. . Proc Natl Acad Sci U S A 107:, 18979–18984. [CrossRef] [PubMed]
    [Google Scholar]
  26. WHO ( 2013; ) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Geneva, Switzeland:: WHO;. http://www.who.int/influenza/human_animal_interface/EN_GIP_20131008CumulativeNumberH5N1cases.pdf
    [Google Scholar]
  27. Yewdell J. W., Bennink J. R., Smith G. L., Moss B.. ( 1985; ). Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. . Proc Natl Acad Sci U S A 82:, 1785–1789. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.058636-0
Loading
/content/journal/jgv/10.1099/vir.0.058636-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error